Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | S100A4 | P26447 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Napabucasin SCHEMBL1883845 | 1.00 | STAT3 (1.00) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL19597404 | 0.89 | STAT3 (0.79) | STAT3ALDH1A1MAPTHTTLMNA | |
| Napabucasin SCHEMBL3654300 | 0.88 | STAT3 (0.78) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL16917433 | 0.86 | STAT3 (0.76) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL12640087 | 0.86 | STAT3 (0.75) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL12494612 | 0.85 | STAT3 (0.73) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL12640086 | 0.84 | STAT3 (0.73) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL18691843 | 0.84 | STAT3 (0.73) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL29364489 | 0.83 | STAT3 (0.71) | STAT3ALDH1A1MAPTHTTLMNA | |
| SCHEMBL29362059 | 0.83 | STAT3 (0.71) | STAT3ALDH1A1MAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010883-A | Napabucasin derivative with double-target anti-tumor activity and preparation method and application thereof | 中国海洋大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | TECHNION RES & DEV FOUNDATION (IL) | 2026-03-05 | — | — | US | claimed |
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260023070-A1 | OPTOGENETIC ALPHA-SYNUCLEIN AGGREGATION SYSTEM-BASED COMPOUND SCREENING PLATFORM IN PD-hiPSC-mDA NEURONS | UNIV JOHNS HOPKINS (US) | 2026-01-22 | — | — | US | claimed |
| WO-2025245413-A1 | IDENTIFICATION OF HIGH MORTALITY SUB-PHENOTYPES OF PEDIATRIC MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) FOR MANAGEMENT AND TREATMENT THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4251133-B1 | COMBINED THERAPY AGAINST CANCER | UNIV CATALUNYA POLITECNICA (ES) | 2025-09-24 | — | — | EP | claimed |
| EP-3957631-B1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2025-09-10 | — | — | EP | claimed |
| EP-4021581-A1 | KMT2A-MAML2 FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-20220193067-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-23 | — | — | US | claimed |
| US-20220193066-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-23 | — | — | US | claimed |
| WO-2022112206-A1 | COMBINED THERAPY AGAINST CANCER | UNIVERSITAT POLITÈCNICA DE CATALUNYA (ES) | 2022-06-02 | — | — | WO | claimed |
| EP-4000600-A1 | COMBINED THERAPY AGAINST CANCER | Universitat Politècnica de Catalunya (ES) | 2022-05-25 | — | — | EP | claimed |
| EP-3973963-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3973964-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-03-30 | — | — | EP | claimed |
| EP-3967310-A1 | QUINOLINE DERIVATIVE USED FOR SOFT TISSUE SARCOMA COMBINATION THERAPY | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-03-16 | — | — | EP | claimed |
| US-20220072013-A1 | Pharmaceutical Combinations for the Treatment of Cancer | CA*TX, INC. | 2022-03-10 | — | — | US | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | DNER, EGFR, NOTCH2 | STAT3 560/4885ALDH1A1 4749/4885MAPT 1486/4885 |
| US-20220193067-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | EWSR1, SALL4, ABL1 | STAT3 193/4885ALDH1A1 857/4885MAPT 4380/4885 |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | CHRM1, CHRNA6, OPRM1 | STAT3 4826/4885ALDH1A1 3314/4885MAPT 277/4885 |
| US-20220072013-A1 | Pharmaceutical Combinations for the Treatment of Cancer | APC, TP53, VHL | STAT3 856/4885ALDH1A1 2278/4885MAPT 1619/4885 |
| US-20260023070-A1 | OPTOGENETIC ALPHA-SYNUCLEIN AGGREGATION SYSTEM-BASED COMPOUND SCREENING PLATFORM IN PD-hiPSC-mDA NEURONS | SNCA, MAP1LC3B, MAPT | STAT3 2062/4885ALDH1A1 2575/4885MAPT 3/4885 |
| US-20220193066-A1 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, KRAS | STAT3 1603/4885ALDH1A1 3069/4885MAPT 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.